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Abstract
The type I interferon (IFN) system is critical for protecting the mammalian host from numerous
virus infections and plays a key role in shaping the anti-viral adaptive immune response. In this
report, the importance of type I IFN signaling was assessed in a mouse model of alphavirus-
induced humoral immune induction. Venezuelan equine encephalitis virus replicon particles
(VRP) expressing the hemagglutinin (HA) gene from influenza virus (HA-VRP) were used to
vaccinate both wildtype (wt) and IFN α/β receptor knockout (RKO) mice. HA-VRP vaccination
induced equivalent levels of flu-specific systemic IgG, mucosal IgG, and systemic IgA antibodies
in both wt and IFN RKO mice. In contrast, HA-VRP vaccination of IFN RKO mice failed to
induce significant levels of flu-specific mucosal IgA antibodies at multiple mucosal surfaces. In
the VRP adjuvant system, co-delivery of null VRP with ovalbumin (OVA) protein significantly
increased the levels of OVA-specific serum IgG, fecal IgG, and fecal IgA antibodies in both wt
and RKO mice, suggesting that type I IFN signaling plays a less significant role in the VRP
adjuvant effect. Taken together, these results suggest that, 1) at least in regard to IFN signaling,
the mechanisms which regulate VRP-induced immunity differ when VRP are utilized as
expression vectors as opposed to adjuvants, and 2) type I IFN signaling is required for the
induction of mucosal IgA antibodies directed against VRP-expressed antigen. These results
potentially shed new light on the regulatory networks which promote immune induction, and
specifically mucosal immune induction, with alphavirus vaccine vectors.
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1. INTRODUCTION
The type I interferons (IFNs) are a family of pleiotropic cytokines which were originally
identified for their ability to interfere with virus replication [1], and are now known to
provide the first line of defense against numerous viral pathogens [2]. Type I IFNs, which
include IFNα and IFNβ, signal through a common receptor, the type I IFN receptor, which
is expressed on almost all cell types [3]. The importance of IFN signaling in antiviral
defense is evidenced by the observation that animals with an engineered genetic deficiency
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in the IFNα/β receptor (IFNα/β receptor knockouts, or RKOs) are acutely susceptible to
numerous viral infections [4–7].
In addition to its role in innate immunity, it has recently been appreciated that type I IFN
signaling also plays an important role in the activation of adaptive immune responses [8–
12]. Type I IFN provides a powerful activation signal to differentiated dendritic cells (DCs),
promoting co-stimulatory molecule expression and their antigen-presenting-cell (APC)
function [12]. Moreover, interferon-treated DCs, upon interacting with B cells, activate
immunoglobulin (Ig) class switch recombination and Ig secretion [13] to multiple isotypes,
including IgA [14]. In addition to effects on DCs, IFN signaling is directly required for
complete activation of B cells [15], CD4+ T cells [16], CD8+ T cells [17], and natural killer
cells [18].
Vaccine vectors based on the alphavirus, Venezuelan equine encephalitis virus (VEE),
contain a message-sense, single-stranded RNA genome [19] and have proven to be
efficacious inducers of antigen-specific immunity in several pre-clinical vaccination models.
VEE replicon particles (VRP) function as antigen expression vectors, encoding a modified
genome in which the structural genes are replaced with a heterologous antigen [20].
Following VRP infection, the replicon RNA encoding the transgene is expressed at very
high levels in the first infected cells; however, progeny virions are not produced. VRP
stimulate potent systemic and mucosal antibody responses directed against both the antigen
carried in the viral genome and soluble antigens simultaneously delivered during a
concomitant VRP infection ([21–23]; Thompson et al., submitted).
A specific role for type I IFN signaling in alphavirus-induced adaptive immunity has
previously been established. The activation of B and T lympocytes (as measured by
upregulated CD69 expression) was significantly impaired in IFNα/β RKO mice, suggesting
that alphavirus-induced lymphocyte activation is incomplete in the absence of IFN signaling
[24]. Leitner et al. demonstrated a role for type I IFN signaling with an alphavirus replicase-
based vaccine, as this vaccine induced immunity to a “self” tolerant antigen in wildtype
animals; however, failed to induce immunity to the same tolerant antigen in IFNα/β RKO
mice [25]. An additional study performed by Restifo and colleagues suggested that the
ability of replicase-based vaccines to break immunological tolerance was dependent upon a
single interferon stimulated gene, RNaseL [26]. Moreover, Hidmark et al. recently
demonstrated that the systemic IgG adjuvant effect of SFV replicon particles is dependent
upon type I IFN signaling, as SFV replicons failed to augment serum IgG responses directed
against co-delivered antigen in IFNα/β RKO mice.
In this report we have evaluated the role of type I IFN signaling in the stimulation of
systemic and mucosal antibody responses by VRP as expression vectors, expressing the
hemagglutinin (HA) gene from influenza (flu) virus (HA-VRP), and as adjuvants, following
co-delivery of null VRP with soluble ovalbumin (OVA). HA-VRP induced equivalent flu-
specific systemic IgG andc IgA antibody responses in both wildtype (wt) and IFNα/β RKO
mice. In contrast, while HA-VRP vaccinated, wt mice produced strong flu-specific IgA
responses at several mucosal surfaces, mucosal IgA responses were barely detectable in
vaccinated IFNα/β RKO mice. Interestingly, null VRP significantly augmented OVA-
specific serum IgG and fecal IgA antibodies in both wt and IFNα/β RKO mice. These
results suggest that type I IFN signaling plays an important role in VRP expression vector-
induced mucosal IgA responses; however, only a minimal role in the VRP adjuvant effect.
This analysis offers a new perspective on the precise role of the IFN pathway in alphavirus-
induced immunity.
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2. MATERIALS AND METHODS
2.1. VEE replicon constructs
The construction and packaging of VRP was performed as previously described [20, 27].
Briefly, confluent monolayers of BHK-21 cells were co-electroporated with the in-vitro-
transcribed replicon RNA and two defective helper RNAs which express the viral structural
genes in trans. In this study, two different replicon constructs were utilized: 1) VRP
expressing the HA gene from the A/PR/8/34 strain of influenza virus (HA-VRP); and 2)
VRP which lack a functional transgene downstream of the 26S promoter (null VRP) [23].
HA-VRP and null VRP were quantitated by immunocytochemistry of infected BHK cells
with anti-sera against HA [20] and null VRP [23], respectively. All replicon particles
utilized in this study were packaged in the wild-type (V3000) envelope.
2.2. Animals and immunizations
Groups of eight-to-16-week-old 129 Sv/Ev and 129 Sv/Ev IFN α/β receptor knockout
(RKO) mice were immunized in a 0.01 ml volume in the rear footpad as previously
described [23]. Breeder pairs of 129 Sv/Ev animals were obtained from Dr. Barbara Sherry,
North Carolina State University, or were purchased from Taconic Laboratories and breeder
pairs of the RKO animals were obtained from Dr. Herbert Virgin, Washington University.
Animals were immunized at week 0 and week 4 with either HA-VRP or ovalbumin (OVA,
Sigma) in the presence or absence of null VRP as an adjuvant in low endotoxin, filter-
sterilized PBS.
2.3. Antibody-Secreting-Cell (ASC) enzyme-linked immunospot (ELISPOT)
Splenocytes and nasal lymphocytes were prepared from immunized animals as previously
described [23] and evaluated in by ASC ELISPOT assay, modified from Thompson et al
[23]. Briefly, purified influenza virus antigen (500ng/well, Charles River Spafas) was used
to coat 96-well nitrocellulose membrane plates (Millipore) overnight at 4°C. Plates were
blocked for 2 hrs with complete media (10% serum) and two fold dilutions of single cell
suspensions were then added to plates in duplicate and incubated overnight. Plates were
washed, and bound spots were detected by the addition of HRP-conjugated goat anti-mouse
γ or α chain-specific antibodies (Southern Biotechnology Associates), followed by addition
of 3-amino-9-ethylcarazole (AEC, Sigma). ASCs were enumerated with a computerized
ELISPOT plate reader (Immunospot) and data are presented as the number of antigen-
specific ASCs per 106 cells plated.
2.4. Sera, Fecal Extracts, and Vaginal Washes
All sample collection was prepared as previously described [23]. Blood was harvested from
individual animals either from the tail vein, following cardiac puncture, or from the
submandibular plexus, and sera collected following centrifugation in microtainer serum
separator tubes (Becton Dickinson). Fecal extracts and vaginal lavage fluids were prepared
from individual animals as previously described [23]. Samples were analyzed for the
presence of antigen-specific IgG and IgA antibodies via ELISA (see below).
2.5. Enzyme Linked Immunosorbant Assay (ELISA)
ELISAs for influenza- and OVA-specific antibodies were performed on serum, fecal
extracts, and vaginal washes as previously described [23]. Briefly, antigen solutions were
incubated in 96-well plates (Costar) overnight at 4°C to allow antigens to bind to the plate
and plates were blocked for 2 h for flu or overnight for OVA, at RT. Following removal of
blocking solution, plates were incubated at room temperature for 2 h (flu) or overnight
(OVA) with serial dilutions of individual samples diluted in the appropriate blocking buffer.
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Plates were washed and incubated for 1 h with HRP-conjugated goat anti-mouse γ or α
chain-specific antibodies (Southern Biotechnology Associates or Sigma). Finally, plates
were washed, and developed with O-phenylenediamine dihydrochloride substrate for 30
min. Antibody endpoint titers are reported as the reciprocal of the highest dilution that
resulted in an OD450 ≥ 0.2. Data are presented as the geometric mean ± standard error of the
mean (SEM).
2.6. Statistical Analysis
Antibody titers and ASC values were evaluated for statistically significant differences by the
Mann-Whitney non-parametric test (GraphPad INSTAT). A p value of ≤0.05 was
considered significant. The Bonferroni correction for multiple comparisons was applied to
the data presented in Fig. 3, as appropriate.
3. RESULTS
3.1. Type I IFN signaling is not required for expression-vector-induced systemic immunity
Systemic and mucosal immunity can be induced by VRP used in two different modalities. In
the first instance, VRP express an antigen encoded in the VRP genome (expression vectors).
In the second, the antigen is supplied separately with the VRP contributing a mucosal and
systemic adjuvant effect. We have examined the requirement for a functional type I IFN
system for systemic and mucosal immunity induced by both VRP modalities. Groups of
wildtype (wt) 129 Sv/Ev and IFN receptor knockout (RKO) mice were immunized in the
rear footpad at weeks 0 and 4 with 1×105 infectious units (IU) of VRP expressing the HA
gene from influenza virus (HA-VRP). Two weeks following the second immunization,
animals were sacrificed, and flu-specific systemic immune responses were measured by
serum IgG ELISA and by IgG and IgA spleen ASC ELISPOT assay (Fig. 1). As shown in
Fig. 1A, HA-VRP induced equivalent levels of flu-specific IgG antibodies in the serum of
both wt and RKO mice. Consistent with this finding, similar numbers of flu-specific IgG-
and IgA-secreting cells were evident in the spleens of both wt and RKO mice (Fig. 1B, Fig.
1C). Together, these results suggest that type I IFN signaling is not required for the
induction of systemic immunity, both IgG and IgA, directed against VRP-expressed
antigens.
3.2. Type I IFN signaling is required for expression-vector-induced mucosal IgA responses
VRP expression vectors induce local mucosal IgA responses at multiple mucosal surfaces in
mice including the upper respiratory tract (URT) [23], the gastrointestinal tract [21–23], and
the urogenital tract [23], even when inoculated at a nonmucosal site. Therefore, mucosal
antibody responses also were measured in wt and IFN RKO animals following HA-VRP
delivery (Fig. 2). As observed with systemic IgG, the mucosal IgG response appeared to be
unaffected by the absence of type I IFN signaling with VRP expression vectors, evidenced
by the observation that HA-VRP induced equivalent levels of flu-specific IgG-secreting
cells in the URT in both wildtype and RKO mice (Fig. 2A). In contrast, HA-VRP failed to
induce significant reduced levels of IgA-secreting cells in the upper respiratory tract of RKO
mice as compared to wt mice (Fig. 2B). To determine whether the mucosal IgA defect in the
URT of RKO mice was limited to this single mucosal surface or was also true of other
mucosal surfaces, flu-specific mucosal IgA responses were analyzed in mucosal samples
derived from the gastrointestinal and urogenital tracts. HA-VRP-inoculated RKO mice also
failed to generate significant IgA antibody responses in fecal extracts (Fig. 2C) and vaginal
wash fluids (Fig. 2D). These results suggest that type I IFN signaling plays a critical role in
VRP expression-vector-induced mucosal IgA immunity, while playing only a minimal role,
if any, in systemic immunity under the same experimental conditions.
Thompson et al. Page 4













3.3. Role of type I IFN signaling on the VRP adjuvant effect
While IFN signaling has a clear effect on expression-vector-induced mucosal igA responses,
we next sought to evaluate VRP adjuvant activity in RKO mice. Therefore, groups of wt and
RKO animals were immunized at week 0 and week 4 with 10 μg of OVA alone, or with 10
μg of OVA co-immunized with 1×105 IU null VRP (no transgene) as an adjuvant. Two
weeks following the boost, animals were evaluated for the presence of OVA-specific IgG
antibodies in the serum and OVA-specific IgG and IgA antibodies in fecal extracts as a
measure of systemic and mucosal immunity, respectively (Fig. 3). In the systemic
compartment, the inclusion of VRP in the inoculum significantly adjuvanted the OVA-
specific systemic IgG response in both wt (~100-fold, p=0.0044) and RKO (~30-fold,
p=0.0044) mice, suggesting that IFN signaling does not play a critical role in systemic
immune induction with VRP adjuvants (Fig. 3A). However, VRP adjuvanted responses were
approximately 3-fold higher in wt mice as compared to RKO animals (p=0.025). In the
mucosal compartment, VRP significantly increased fecal IgG (Fig. 3B) and fecal IgA (Fig.
3C) responses to the same extent in both wt and RKO animals, suggesting that, while IFN is
critical for mucosal IgA induction when antigen is supplied from the VRP genome, IFN
signaling plays only a minimal role in the VRP adjuvant effect.
4. DISCUSSION
While the utility of VRP as a component of successful vaccines has clearly been established,
little is known regarding the critical immunological factors which regulate VRP-induced
immune induction. Here we present evidence that type I IFN signaling plays an important
role in VRP-induced immune stimulation; specifically in the induction of mucosal IgA
responses directed towards VRP-expressed antigen.
Our studies suggest that, at least in regard to the IFN system, the mechanisms which regulate
immune induction to antigens expressed from alphavirus replicon particles are distinct from
the immunoregulatory mechanisms operative when replicon particles are utilized as
adjuvants. This notion is supported by the results presented here that mucosal IgA responses
induced by VRP expression vectors are significantly impaired in RKO mice; however,
mucosal IgA responses directed against VRP adjuvanted antigen in RKO were equivalent to
wildtype mice. Although Hidmark et al. did not measure mucosal IgA responses, these
authors also report a differential effect of the RKO defect on SFV-expressed, compared to
replicon adjuvanted vaccines. The authors demonstrated that serum IgG responses directed
against expressed antigen were equivalent between wildtype and RKO animals; however,
the serum IgG adjuvant effect with SFV replicon particle was abrogated in RKO mice [28].
Together, these results are consistent with a model in which alphavirus replicon particles
rely on distinct mechanisms for immune induction when utilized as expression vectors
versus adjuvants.
While work with replicon particles derived from VEE and SFV has unveiled their dual
utility as both expression vectors and adjuvants, important differences exist between results
obtained with the two viral systems. The SFV serum IgG adjuvant effect was completely
abrogated in RKO mice [28]. This was not the case in the VEE system, as serum adjuvant
activity was observed in RKO mice, albeit decreased approximately 3-fold compared to
wildtype mice. To date, the mechanistic explanation regarding the differences between VEE
and SFV have yet to be determined; however, several possibilities exist. One plausible
explanation is that the initial targets of infection shape the dependence on IFN signaling for
immune induction. VRP efficiently infect DCs both in vitro [29] and in vivo [30], (West, A.,
Whitmore, A., Moran, T., and Johnston, R., unpublished). In contrast, SFV does not appear
to efficiently infect DCs in vitro, even at an MOI as high as 1000 [31], and in vivo infection
of DCs by SFV has not been reported.
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Other more subtle effects could also account for the differences observed between VEE and
SFV. For example, both viruses induce type I IFN; however a careful comparison of the
absolute levels of IFN induced by both viruses has not been performed. Additionally,
mammals encode multiple IFN α genes [8] and it is unclear exactly what role each
individual α gene plays both in antiviral defense and activation of adaptive immunity It is
possible that a distinction exists in the overall levels of IFN and/or the IFN α gene repertoire
induced by VEE and SFV, and that this feature may account for the observed differential
immunogenicity between the two systems. Future experimentation in both systems will be
required to fully elucidate the role of IFN in alphavirus-induced immunity.
The observation that IFN directly serves as a an adjuvant for the induction of antibody
responses, and IgA responses, to co-immunized antigen is consistent with a role for IFN in
alphavirus-induced immunity [13, 32–34]. However, the mechanism by with IFN
specifically promotes mucosal IgA responses following delivery of VRP expression vectors
is unclear. Here we propose that IFN functions downstream of IgA class switch, as normal
IgA responses were observed in the systemic compartment (spleen) and in the draining
lymph node (data not shown) of HA-VRP-immunized RKO mice. These observations are
consistent with a model in which IFN signaling promotes VRP-induced mucosal migration
of IgA-secreting B cells under conditions in which the antigen expressed in VRP-infected
cells. Further studies will be required to address the validity of this hypothesis.
An important point to consider in the interpretation of immune induction experiments in
RKO mice is the amount of VRP-driven antigen expressed in both wildtype and RKO mice.
It is known that alphavirus vector-expressed antigen is markedly increased in animals
lacking the type I receptor ([25]; White et al., in preparation), suggesting that, in wt mice,
autocrine and paracrine IFN signaling limit alphavirus vector antigen expression [25]. In
experiments presented here, we concluded that IFN was not required for expression-vector-
induced systemic immunity; however, this interpretation includes the caveat that equivalent
systemic immune responses against the encoded antigen were induced under conditions in
which antigen expression levels were greatly increased in RKO mice. However, in the case
of mucosal IgA responses induced in RKO mice with VRP expression vectors, a significant
defect was observed in RKO mice even though much more antigen was present,
demonstrating that increased antigen levels cannot replace the function of IFN signaling in
this system.
In this report we provide further evidence for a role of the type I IFN system in alphavirus-
induced adaptive immunity. Type I IFN played a critical role in the activation of mucosal
IgA responses following delivery of VRP expression vectors, possibly via regulating
mucosal migtration. Identification of the precise mechanism by which IFN promotes VRP-
induced mucosal IgA should lead to both a basic understanding of the factors involved in
virus-induced immunity as well as new strategies to increase the efficacy of VRP as mucosal
vaccine vectors.
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Figure 1. Type I IFN signaling is dispensable for expression-vector-induced systemic immunity
Groups of wt and RKO mice were immunized in the rear footpad at weeks 0 and 4 with
1×105 IU of HA-VRP. Two weeks following the boost, flu-specific serum IgG antibodies
were evaluated by ELISA (A). Additionally, splenocytes were evaluated for the presence of
flu-specific IgG- (B) and IgA- (C) secreting cells by ASC ELISPOT. Values represent the
geometric mean ± SEM. No statistically-significant differences exist between responses
induced in wt and RKO animals.
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Figure 2. Type I IFN signaling is required for expression-vector-induced mucosal IgA responses
Groups of wt and RKO mice were immunized in the rear footpad at weeks 0 and 4 with
1×105 IU of HA-VRP. Two weeks following the boost, nasal lymphocytes were evaluated
for the presence of flu-specific IgG- (A) and IgA- (B) secreting cells by ASC ELISPOT.
Additionally, levels of flu-specific IgA antibodies were evaluated in fecal extracts (C) and
vaginal lavage fluids (D) by ELISA. Values represent the geometric mean ± SEM. *,
p=0.0286 compared to wt mice, as determined by Mann-Whitney.
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Figure 3. Role of type I IFN signaling on the VRP adjuvant effect
Groups of wildtype (wt) and IFN α/β receptor knockout (RKO) mice were immunized in the
rear footpad at weeks 0 and 4 with OVA alone, or OVA plus 1×105 IU of null VRP. Two
weeks following the boost, OVA-specific serum IgG (A), fecal IgG (B), and fecal IgA (C)
antibody responses were evaluated by ELISA. Values represent the geometric mean ±
SEM. *, p=0.025 compared to OVA plus VRP in wt mice; **, p=0.0044 compared to OVA
alone, as determined by Mann-Whitney. The Bonferroni correction for multiple comparisons
was applied to the reported p values.
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